Osimertinib (AZD9291)

For research use only.

Catalog No.S7297 Synonyms: Mereletinib

237 publications

Osimertinib (AZD9291) Chemical Structure

CAS No. 1421373-65-0

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 147 In stock
USD 97 In stock
USD 135 In stock
USD 700 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Osimertinib (AZD9291) has been cited by 237 publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Features Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
Targets
L858R/T790M EGFR [1]
(LoVo cells)
Exon 19 deletion EGFR [1]
(LoVo cells)
WT EGFR [1]
(LoVo cells)
11.44 nM 12.92 nM 493.8 nM
In vitro

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-9/BRc1 NIDiV2NHfW6ldHnvckBCe3OjeR?= MYm1NEBvVQ>? MkWwNlQhcA>? MkPhSG1UVw>? MYLpcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/ERc1 NE[0fXlHfW6ldHnvckBCe3OjeR?= NHv1ZZY2OCCwTR?= NWjO[YtxOjRiaB?= NYXkR5BTTE2VTx?= NF7PfJZqdmS3Y3XzJIV5eHKnc4Ppc44hd2ZidHjlJJBzd2Gyb4D0c5Rq[yCEQ1ytNkBn[W2rbImgcYVu[mW{IFLJUS=> MlrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
VP-2 NEj4SXlHfW6ldHnvckBCe3OjeR?= M2jVS|UxKG6P MY[yOEBp MXXEUXNQ MV\pcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= M1fyTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N|I2Lz5{NUS3O|MzPTxxYU6=
PC-9/BRc1 NVHTWGRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;hZ|UxKG6P M4L2XlExKGR? NVHUU|NsTE2VTx?= MnribY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm| NEi3UYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O|MzPSd-MkW0O|c{OjV:L3G+
PC-9/ERc1 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELxU4w2OCCwTR?= M4XQSlExKGR? M2LtemROW09? NXP6doFTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBtd26pLYTldo0hMDFyLXThfUkh\3Kxd4ToJIlvcGmkaYTpc44h[XO|YYnz NXqyXJJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjNOIk2OCCwTR?= M1TvVlExKGR? NGLYNGxFVVOR MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC9 GR4 MW\GeY5kfGmxbjDBd5NigQ>? M{[4RlAuOTBizszN M2rrPFczKGh? MmLibY5pcWKrdIRCpGVITlJicHjvd5Bpd3K7bHH0bY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[:Kh NVPWXoFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN|PD;hQi=>
PC9 MX7GeY5kfGmxbjDBd5NigQ>? NF7EW4IxNTFyIN88US=> MVO3NkBp NI\u[WJqdmirYnn0d{BYXCCHR1\SJIF1KGyxdzDjc45k\W62cnH0bY9vew>? MoPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N|MoRjJ3OUS4OlM{RC:jPh?=
PC9 GR4 NIfyeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYWHl2OC1zMDFOwG0> NUPPWotTPzJiaB?= NFfrRXFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NFy0OGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0PFY{Oyd-MkW5OFg3OzN:L3G+
BAF3 NYD2VnBXTnWwY4Tpc44h[XO|YYm= Mo\OO|IhcA>? MUXHTVUxKD1iMD6wNFA{KM7:TR?= NV;jeno4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 NGn3XWNHfW6ldHnvckBie3OjeR?= NIPuV|A4OiCq NHrPcZZIUTVyIE2gNE4xODB|IN88US=> NUfjbo1RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 M{HXe2Z2dmO2aX;uJIF{e2G7 NXLxXnFGPzJiaB?= MV7HTVUxKD1iMD6wNFEh|ryP MkW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827 NIPmc5BHfW6ldHnvckBie3OjeR?= MXO3NkBp NYny[GxsT0l3MDC9JFAvODBzIN88US=> NFvscJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9 MVTGeY5kfGmxbjDhd5NigQ>? M3nhVlczKGh? MmjTS2k2OCB;IECuNFAzKM7:TR?= NWDKUWt6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 MUTGeY5kfGmxbjDhd5NigQ>? MmP0OEBp MYjFR|UxKD1iMD6wNFIh|ryP NUn4N2V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827 MV\GeY5kfGmxbjDhd5NigQ>? M4TZfFMhcA>? NYqyfIppUUN3MDC9JFAvODB{NTFOwG0> MlKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
H1975 MVTGeY5kfGmxbjDhd5NigQ>? NVW4OmIxOyCq NF7jPWZKSzVyIE2gNE4xODJ3IN88US=> MkCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
H3255 M4K3NWZ2dmO2aX;uJIF{e2G7 MXezJIg> NHLKO5FKSzVyIE2gNE4xODRzIN88US=> M1j3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN|gzQTxxYU6=
NCI-H1975 NGWwW2VHfW6ldHnvckBie3OjeR?= MVO3NkBp MlvHS2k2OCB;IECuNFA2KM7:TR?= NIW0cXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9 M{fYTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MV:3NkBp NI\FeVlKSzVyIE2gNE4xODZ3IN88US=> NEi4PJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
NCI-H1975 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NEfjTZU4OiCq NV3tbnlGUUN3MDC9JFAvODFyNTFOwG0> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
Sf21 NXPHRmR1TnWwY4Tpc44h[XO|YYm= M1TWVmlEPTBiPTCwMlAyOiEQvF2= M2f4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm2NlY4Lz5{N{m5OlI3PzxxYU6=
PC9-DRH M3nxPWZ2dmO2aX;uJIF{e2G7 NUPyO3JlOiCq Ml;4TWM2OCB;IECuNFE{KM7:TR?= NUn5XldkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
BAF3 M1nlXGZ2dmO2aX;uJIF{e2G7 NGTsNo44OiCq NGrZbXNIUTVyIE2gNE4xOTNizszN MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827 M1TLcmZ2dmO2aX;uJIF{e2G7 M{nIZ|k3KGh? MWTFR|UxKD1iMD6wNVQh|ryP M4TmXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
HCC827 MoLkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MYS5OkBp M1PPbWVEPTBiPTCwMlAyPCEQvF2= M2\LT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
NCI-H1975 M3TTdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M4W1SFk3KGh? NG\aPXBGSzVyIE2gNE4xOTRizszN MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
NCI-H1975 Mn7GSpVv[3Srb36gZZN{[Xl? NEHHZVgzKGh? NFuwd|lKSzVyIE2gNE4xOTVizszN M2mydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
H1975 NVfaSIhwTnWwY4Tpc44h[XO|YYm= NIHpfnEzKGh? MVTJR|UxKD1iMD6wNVUh|ryP NIDLNZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
PC9 M{HO[WZ2dmO2aX;uJIF{e2G7 NV;hXo97OiCq MWnJR|UxKD1iMD6wNVch|ryP M{Tyd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
NCI-H1975 NFn5THFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NHe4NVg4OiCq MVrJR|UxKD1iMD6wNVkh|ryP NV;WSFBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd|PD;hQi=>
NCI-H1975 M4iyN2Z2dmO2aX;uJIF{e2G7 MkXNPVYhcA>? MUnFR|UxKD1iMD6wNVkh|ryP NWrLVlIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
NCI-H1975 M1jibmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NF\JfY86PiCq M4HoT2VEPTBiPTCwMlAyQSEQvF2= NYOxOIlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NFM6QTFpPkK4OlA{QTlzPD;hQi=>
NCI-H1975 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NU\0eIZnPzJiaB?= MUHJR|UxKD1iMD6wNVkh|ryP MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
HCC827 MVnGeY5kfGmxbjDhd5NigQ>? NFfkRYEzKGh? NH3EOoVKSzVyIE2gNE4xOjNizszN M1zmTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975 MljnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NEjSVGw4OiCq MkLPTWM2OCB;IECuNFI{KM7:TR?= M1m2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVI3Lz5{OUWzOFkzPjxxYU6=
PC9 M2\3Z2N6fG:2b4jpZ4l1gSCjc4PhfS=> M3ewWFczKGh? NFXOWG5IUTVyIE2gNE4xOjNizszN NX;oS|RlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
NCI-H1975 NV:2PWZGS3m2b4TvfIlkcXS7IHHzd4F6 NIf3WW44OiCq MWXHTVUxKD1iMD6wNlQh|ryP Mon2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
HCC827 M2LWXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M2nKTFczKGh? NEDqT4ZKSzVyIE2gNE4xOjV2IN88US=> NITmbIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O|YzPzJ:L3G+
HCC827 NG\ob2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mn\LO|IhcA>? NUjxUYp2UUN3MDC9JFAvODJ5IN88US=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
HCC827 MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M3Xue|czKGh? MmPpTWM2OCB;IECuNFI4KM7:TR?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
NCI-H1975 M3nxPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M{jpXlczKGh? NWjxWXh5UUN3MDC9JFAvODNizszN MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{O1O|koRjJ6MEOzOVc6RC:jPh?=
H3255 M2rjNGZ2dmO2aX;uJIF{e2G7 M3Szd|czKGh? NHnCfFJIUTVyIE2gNE4xOzNizszN MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255 MVrGeY5kfGmxbjDhd5NigQ>? NIPpcWwzKGh? MlvwTWM2OCB;IECuNFM3KM7:TR?= NYKwcWNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
NCI-H1975 Ml3WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MWq3NkBp MYfJR|UxKD1iMD6wOFEh|ryP M1jnWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
NCI-H1975 NHzScnFHfW6ldHnvckBie3OjeR?= NV;lWJdbOSCq NInmd2JKSzVyIE2gNE4xPDFizszN M4TseVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVI3Lz5{OUWzOFkzPjxxYU6=
BAF3 M3;sNmZ2dmO2aX;uJIF{e2G7 MV[0JIg> MWLFR|UxKD1iMD6wOFMh|ryP MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NIG4doI4OiCq NFSx[WdKSzVyIE2gNE4xPDd{IN88US=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO|I9N2F-
NCI-H1975 NI\uUY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mn;6O|IhcA>? Ml7PTWM2OCB;IECuNFUzKM7:TR?= Mmq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N|koRjJ5MUOxOlM6RC:jPh?=
PC9 M3\0WWZ2dmO2aX;uJIF{e2G7 MWiyJIg> M3PPbmlEPTBiPTCwMlA2PiEQvF2= NYC3bpVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
NCI-H1975 NFvPV5REgXSxdH;4bYNqfHliYYPzZZk> NHHpUZg4OiCq MXTJR|UxKD1iMD6wOkDPxE1? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827 NFrnUopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NILkW3NKSzVyIE2gNE4xPjF4IN88US=> NVHES|l4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
NCI-H1975 NXfpSFlUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MkTETWM2OCB;IECuNFY4KM7:TR?= MlG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HaCaT NVnZTZVFTnWwY4Tpc44h[XO|YYm= MV6zJIg> NIG5W3hKSzVyIE2gNE4xPzN5IN88US=> NYXBeY9TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N|M5OjlpPkK3OFM{QDJ7PD;hQi=>
NCI-H1975 MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M2rCOVczKGh? M{naWWlEPTBiPTCwMlE{KM7:TR?= MnXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
A431 NEHtWJJHfW6ldHnvckBie3OjeR?= MkfKNUBp MXnJR|UxKD1iMD6xOFEh|ryP NWDCdW9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549 NE\kRYdHfW6ldHnvckBie3OjeR?= NIPaW5lKSzVyIE2gNE4yPSEQvF2= MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
Calu3 NV20NGZvS3m2b4TvfIlkcXS7IHHzd4F6 MXO3NkBp M4rBNmdKPTBiPTCwMlI3PCEQvF2= NV\jW5BORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
Sf9 Mli1SpVv[3Srb36gZZN{[Xl? M3XRWFIxKG2rboO= MUfJR|UxKD1iMD6yO|gh|ryP Mn2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OEKxOVEoRjJ6NEiyNVUyRC:jPh?=
BAF3 NXXic5RVTnWwY4Tpc44h[XO|YYm= M4jHelczKGh? NFrQS3lIUTVyIE2gNE4{KM7:TR?= NFPQWXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3 M4nOeWZ2dmO2aX;uJIF{e2G7 Mmm4O|IhcA>? M4nT[WdKPTBiPTCwMlMyKM7:TR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H460 NH;HeI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MlL5O|IhcA>? MorPTWM2OCB;IECuOFE2QSEQvF2= M4PpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
LoVo MkfpSpVv[3Srb36gZZN{[Xl? MXqyJIg> MXvJR|UxKD1iMD60PEDPxE1? NX7OfJNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV|PD;hQi=>
LoVo M1PXdWZ2dmO2aX;uJIF{e2G7 MnLWNkBp MYjJR|UxKD1iMD60PEDPxE1? MmnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OU[yOlcoRjJ5OUm2NlY4RC:jPh?=
A549 NV7RPG5sSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M2P1ZlczKGh? M130dmlEPTBiPTCwMlQ5PiEQvF2= M{DpNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3 MlTjSpVv[3Srb36gZZN{[Xl? NWXVTZB7PzJiaB?= NX24SGF2T0l3MDC9JFAvPSEQvF2= NEnheHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A549 MnXWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NX3mWVhIPzJiaB?= MlvoTWM2OCB;IECuOVMh|ryP MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
A549 NX\Zeo54S3m2b4TvfIlkcXS7IHHzd4F6 MWi3NkBp MWfJR|UxKD1iMD61N{DPxE1? Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
BAF3 M2PsWWZ2dmO2aX;uJIF{e2G7 NXexR5ROPzJiaB?= MlnOS2k2OCB;IECuOVUh|ryP NXrmfHFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 NU\HOWhsTnWwY4Tpc44h[XO|YYm= MWW3NkBp M{PNSWdKPTBiPTCwMlU3KM7:TR?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HEK293 M2[2WmZ2dmO2aX;uJIF{e2G7 MWrJR|UxKD1iMD61O{DPxE1? M2LQT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3 MUPGeY5kfGmxbjDhd5NigQ>? MlrQO|IhcA>? M4PjfWdKPTBiPTCwMlU6KM7:TR?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A431 M3r4NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M13nc2lEPTBiPTCwMlYyPTZizszN NIj5SWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
HT-29 NIO3PWREgXSxdH;4bYNqfHliYYPzZZk> MoH6O|IhcA>? NHzVU5pKSzVyIE2gNE43PSEQvF2= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431 NH65UItHfW6ldHnvckBie3OjeR?= MVK5OkBp M{D5[mVEPTBiPTCwMlY3PyEQvF2= MnHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkWyOlkoRjJ6MkK1NlY6RC:jPh?=
A431 NVfMTY1nSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGHWW4Y6PiCq MYjFR|UxKD1iMD62O{DPxE1? NIDlVIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
A431 MkDLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NGj5cYk4OiCq MlHvTWM2OCB;IECuOlg2KM7:TR?= MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
A431 NXPaUFk6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MWS5OkBp NUW3WG9vTUN3MDC9JFAvPyEQvF2= Moe3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
A549 NE\uWpNEgXSxdH;4bYNqfHliYYPzZZk> MWi3NkBp MmewTWM2OCB;IECuPFch|ryP NV;tR5lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV|PD;hQi=>
A431 NGDY[olCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MXe3NkBp NGLDd|JKSzVyIE2gNE45QTNizszN MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MU[zPUc,OjdzM{G2N|k9N2F-
BA/F3 M3vnNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NWLlS|FTPzJiaB?= NETubFNKSzVyIE2gNUDPxE1? NE[ybGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
BAF3 NXzhW2h7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{nwelczKGh? NFK0OnZIUTVyIE2gNU4zKM7:TR?= NGDzVVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H2122 MXnGeY5kfGmxbjDhd5NigQ>? MoLXO|IhcA>? NHzV[FBIUTVyIE2gNU4zKM7:TR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A431 NE\n[oRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NXXJNoJSPzJiaB?= NInVT25KSzVyIE2gNU4zPCEQvF2= M1\uelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
A431 M4PaSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NEK0b4U4OiCq M2Cx[WlEPTBiPTCxMlI3KM7:TR?= MofIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{CxPVIoRjJ7N{OwNVkzRC:jPh?=
A431 MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M{DCZ|czKGh? NFvlS|dKSzVyIE2gNU43ODRizszN NXvhdFB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN|M2PzlpPkK4NFM{PTd7PD;hQi=>
A549 M{TWW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M1rHNlk3KGh? Mke5SWM2OCB;IEGuPFMh|ryP M{\UXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
CHL MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PCRVczKGh? MXfHTVUxKD1iMj65JO69VQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1355 M3PpdWZ2dmO2aX;uJIF{e2G7 M2e0d|czKGh? M3jKe2dKPTBiPTCzJO69VQ>? MkHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1703 Mmn4SpVv[3Srb36gZZN{[Xl? M3PoR|czKGh? MV;HTVUxKD1iMz61JO69VQ>? M2PC[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549 MWnGeY5kfGmxbjDhd5NigQ>? MmjOO|IhcA>? NWPIc3R3T0l3MDC9JFMvPSEQvF2= NW\QN3hyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
CHO MljoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHzpO3U4OiCq M1\KSGdKPTBiPTC0MlIh|ryP NXT1[4VlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 M2\Z[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MYG3NkBp NEXMdIVKSzVyIE2gOE43OSEQvF2= MojkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BAF3 NV;WR3h6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NXyxbXFPPzJiaB?= MYPJR|UxKD1iNT6xOUDPxE1? NX;pdlF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BEAS2B M4m0OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MUK3NkBp M2W2e2lEPTBiPTCxOE46KM7:TR?= NVHKOWVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O|E3PjRzPD;hQi=>
NCI-H1975 Mm\ZSpVv[3Srb36gZZN{[Xl? NWm0eXRHOiCq M1jjPWlEPTBiPTCxOUDPxE1? MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
PC9 M3:2V2Z2dmO2aX;uJIF{e2G7 MU[yJIg> MXvJR|UxKD1iMUeg{txO NHHVNZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
LoVo MYnGeY5kfGmxbjDhd5NigQ>? NYe0PJJsOiCq NULmb2UzUUN3MDC9JFQ5OCEQvF2= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975 NHLqNXVCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= M3SwfmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOi53IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s NV3lRoM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
rat hepatocytes MoT5SpVv[3Srb36gZZN{[Xl? MnLlTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK|Yh[2WubIO= NH\FTmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
human hepatocytes MWHGeY5kfGmxbjDhd5NigQ>? NWrTUnhsUW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDt[YF{fXKnZDDw[ZIhOTBpNjDj[Yxtew>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975 M4D4S2FvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?= NH\5V2pCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDVibXevb4cw\GG7LDDwc{By\CCob4KgO{Bl[Xm|IILlcIF1cX[nIITvJINwdnS{b3y= MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975 NHz1fGVHfW6ldHnvckBie3OjeR?= NUW1[4RWW2WuZXP0bZZqfHliaX7k[ZgtKHKjdHnvJI9nKEmFNUCg[o9zKEWJRmKgWFc6OE1xTEi1PHIh\G:3YnzlJI12fGGwdDDlfJBz\XO|aX7nJIh2dWGwIF7DTU1JOTl5NTDj[YxteyC2bzDJR|UxKG[xcjD3bYxlKHS7cHWgSWdHWiCneIDy[ZN{cW6pIHj1cYFvKEF2M{GgZ4VtdHN? M1;KSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
NCI-H1975 M1fOUGFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?= MY\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDFS2ZTKFR5OUDNM2w5PTiUIHTveYJt\SCvdYThcpQh\XiycnXzd4lv\yCqdX3hckBPS0lvSEG5O|Uh[2WubIOgfIVvd2e{YX\0[YQhcW5iQlHMRk9kKGG2aIntbYMhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZzygdI8h[mmmIH\vdkAzOSCmYYnz M3nadVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827 MXPBdI9xfG:|aYOgZZN{[Xl? M1jMe2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOg[YFzdHliYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEGuN|QmMQ>? MnPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
HCC827 MlnYRZBweHSxc3nzJIF{e2G7 NEPzbZdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIxifGViYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEK3MlE1LSl? NU[wfXRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd|PD;hQi=>
A549 NX;TbYhSTnWwY4Tpc44h[XO|YYm= NVrGe4FPW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hSTV2OTDj[YxteyCneIDy[ZN{cW6pIIfpcIQufHmyZTDFS2ZTN0tvUnHzJI12fGGwdDD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ> MlXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827 MoDnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3;xT|czKGh? MnvNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ1O4Nlch[2WubIOgZZQhOSC3TTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO|I9N2F-
BAF3 NHu5S3lHfW6ldHnvckBie3OjeR?= NFrxWGkzKGh? NYHFXmxzUW6qaXLpeIlwdiCxZjDFS2ZTKFR5OUDNM2w5PTiUL1O3PVdUKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBGT0ZvaX7keYNm\CC{ZXPldJRweiCyaH;zdIhwenmuYYTpc44h[XRiMTD0c{A{KHWPIIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliRVfGJJN1cW23bHH0bY9vKG[xcjCxOUBucW6|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? M1T6XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
BAF3 MoSySpVv[3Srb36gZZN{[Xl? NFzsSowzKGh? NV7tOZd6UW6qaXLpeIlwdiCxZjDFS2ZTKDF7RD;UO|kxVS:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
NCI-H1975 M3vGNmFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?= NXHVZlZKSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy|IIjlco9oemGodHXkJIlvKFOWT1PLMWZwgG5zboWvUop2KG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dX3vdkBoem:5dHigZZQhOjBibXevb4cw\GG7LDDwc{By\CCob4KgNVQh\GG7czDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=> NH3s[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIyQSd-MkizPVUzOTl:L3G+
Caco2 M4TpWGZ2dmO2aX;uJIF{e2G7 MWSyJIg> MY\F[oZtfXhicnH0bY8hd2ZiYYDwZZJmdnRicHXycYVi[mmuaYT5JIZzd21iYnHzc4xifGW{YXygd4ll\SC2bzDhdIlk[Wxic3nk[UBwfmW{IHHwbYNidCC|aXTlJJRwKGKjc3;sZZRmemGuIIPp[IUhd3[ncjDpckBpfW2jbjDDZYNwOiClZXzsd{BifCB3IIXNJIlv[3WkYYTl[EBnd3JiMjDodpM> NY\Nc4FXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
A431 MUHGeY5kfGmxbjDhd5NigQ>? NWr2NHJXW2WuZXP0bZZqfHlicnH0bY8hd2ZiRVO1NEBnd3JiaIXtZY4hSTR|MTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZTKHSxIFXDOVAh\m:{IHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUj3MPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62 NX7tXFhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
Caco2 MXrGeY5kfGmxbjDhd5NigQ>? M{HkbFIhcA>? NGPYSGFCeHCjcnXueEBx\XKvZXHibYxqfHliYXPyc5N{KGGyaXPhcEB1dyCkYYPvcIF1\XKjbDDzbYRmKGmwIHj1cYFvKEOjY3:yJINmdGy|IHH0JFUhfU1iaX7jeYJifGWmIH\vdkAzKGi{cx?= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
Caco2 Mom5SpVv[3Srb36gZZN{[Xl? M3u5RVIhcA>? NYfDdodwSXCyYYLlcpQheGW{bXXhZoltcXS7IHHjdo9{eyCkYYPvcIF1\XKjbDD0c{BieGmlYXygd4ll\SCrbjDoeY1idiCFYXPvNkBk\WyuczDheEA2KHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoO= MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
NCI-H1975 M4fN[GZ2dmO2aX;uJIF{e2G7 M1LnelQhcA>? NVzqfZJOUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfCCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFsfCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5N1OnckS3N{B{cXSnIHH0JFEhfU1ibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NH;5T4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 MWHGeY5kfGmxbjDhd5NigQ>? MVm0JIg> NE\z[ZVKdmirYnn0bY9vKG:oIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgbY4hcHWvYX6gTGNEQDJ5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBCc3RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQC:VZYK0O|Mhe2m2ZTDheEAyKHWPIH3lZZN2emWmIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 NV3FZmNVSXCxcITvd4l{KGG|c3H5 M4XvSVQ5KGh? MUnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBufXSjboSgZZN{\XO|ZXSgZZMh[2G|cHHz[VMh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd? Moe2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827 MWrBdI9xfG:|aYOgZZN{[Xl? MoPyOFghcA>? NI[yc5lKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDlfI9vKDF7IHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDjZZNx[XOnLUOgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9 MWjBdI9xfG:|aYOgZZN{[Xl? M2CzO|Q5KGh? MoS0TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO|ZXSgZZMh[2G|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK|IHL5JIludXWwb3Lsc5R1cW6p MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255 NF6wSGdCeG:ydH;zbZMh[XO|YYm= M1L3W|Q5KGh? M3vLfmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSEOyOVUh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIhdXW2YX70JIF{e2W|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?= NWnsUGw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975 MYTBdI9xfG:|aYOgZZN{[Xl? NH;aeJI1QCCq NEL3NohKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO|kxVSCvdYThcpQh[XO|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? NXjWWoNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9 NG\vOWFCeG:ydH;zbZMh[XO|YYm= Mn\QOFghcA>? NGPpVI9KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827 M1j1c2Fxd3C2b4Ppd{Bie3OjeR?= MYG0PEBp MVjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255 NV3iUYk4SXCxcITvd4l{KGG|c3H5 Mk\VOFghcA>? NUHG[pdrUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIN|I2PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5WiCvdYThcpQh[XO|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? M3n2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 M1fGXGZ2dmO2aX;uJIF{e2G7 M1HERXNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KHSxIFnDOVAh\m:{IHj1cYFvKEF2M{GgZ4VtdHNiaHHyZo9zcW6pIIfpcIQufHmyZTDFS2ZT M3\2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
human hepatocytes Mke2SpVv[3Srb36gZZN{[Xl? NEDaOlZKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIHj1cYFvKGincHH0c4N6fGW|IHHzd4V{e2WmIIDldkBucWyuaX;uJINmdGy| M4fYe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
rat hepatocytes MlTtSpVv[3Srb36gZZN{[Xl? NVHOS401UW62cnnud4lkKGOuZXHyZY5k\SCrbjDyZZQhcGWyYYTvZ5l1\XNiYYPz[ZN{\WRicHXyJI1qdGyrb36gZ4VtdHN? M3\kbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
A549, NCI-H1975 MmXZSpVv[3Srb36gZZN{[Xl? M2[x[nNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHnuJIh2dWGwIF7DTU1JOTl5NTDj[Yxtew>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
A549, PC9 NFXrbJpHfW6ldHnvckBie3OjeR?= M1rmbXNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iUFO5JINmdGy| NX63XGJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
HCC827 NHrIW5NCeG:ydH;zbZMh[XO|YYm= MluxTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0OkB1dyCDN{WwJIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bm[XKueTDhdI9xfG:2aXOgZ4VtdHNiYYSgN{B2VSCjZoTldkAzPCCqcoOgZpkhSW6wZYjpckBXNU[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTyfUApWn[kIE2gNU4{PCC2bzCxMlY4LSl? NVjMeYhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975 NXnHUpJNTnWwY4Tpc44h[XO|YYm= M{nRZ2lvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO|kxVSCmb4XicIUhdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCQQ1mtTFE6PzViY3XscJMh[XRiMTD0c{AyODBibl2gZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? M1XYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUC2NVE1Lz5{OUmwOlEyPDxxYU6=
A431 MnfUSpVv[3Srb36gZZN{[Xl? NVziWHl7W2WuZXP0bZZqfHlicnH0bY8tKHKjdHnvJGlEPTBiZn;yJIh2dWGwIFG0N|Eh[2WubIOgc5ZmemW6cILld5Nqdmdid3ns[E11gXCnIFXHSnIhfG9iSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIV5eHKnc4PpcochTUeIUjDUO|kxVS:OOEW4VkBufXSjboS= Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N|koRjJ5MUOxOlM6RC:jPh?=
PC9 NHf4RVBCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= MUnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s NHnTWng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
A431 NEX6fVdCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= NUHldFVHSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDVibXevb4cw\GG7LDDwc{By\CCob4KgO{Bl[Xm|IILlcIF1cX[nIITvJINwdnS{b3y= NXjPZoZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / p-AKT / p-ERK; 

PubMed: 28416483     


PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib.

ABCB1; 

PubMed: 27649127     


The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.

28416483 27649127
Growth inhibition assay
Cell viability; 

PubMed: 31043587     


Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. *P < 0.05, **P < 0.01, ***P < 0.005 by t-test.

31043587
Immunofluorescence
Ki67 / γH2AX / p16; 

PubMed: 29212784     


PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. **P ≤ 0.01, ***P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.

29212784
In vivo AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Mice bearing PC9 and H1975 xenograft tumors
  • Dosages: ~5 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 99 mg/mL warmed (198.15 mM)
Water Insoluble
Ethanol '43 mg/mL warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
7.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 499.61
Formula

C28 H33 N7 O2

CAS No. 1421373-65-0
Storage powder
in solvent
Synonyms Mereletinib
Smiles CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02841579 Completed Drug: Osimertinib Non-Small Cell Lung Cancer MedSIR|AstraZeneca August 2016 Phase 2
NCT02771314 Unknown status Drug: AZD9291 Non Small Cell Lung Cancer Hellenic Oncology Research Group August 2 2016 Phase 2
NCT02529995 Completed Drug: AZD9291 40 mg|Drug: AZD9291 80 mg Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive AstraZeneca August 24 2015 Phase 1
NCT02491944 Completed Drug: AZD9291|Drug: [14C]AZD9291 Oncology AstraZeneca July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

  • Answer:

    Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFR Signaling Pathway Map

Related EGFR Products

Tags: buy Osimertinib (AZD9291) | Osimertinib (AZD9291) supplier | purchase Osimertinib (AZD9291) | Osimertinib (AZD9291) cost | Osimertinib (AZD9291) manufacturer | order Osimertinib (AZD9291) | Osimertinib (AZD9291) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID